Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antibiotic Selection00:57

Antibiotic Selection

Overview
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Microbiota Modulation by Antibiotics01:21

Microbiota Modulation by Antibiotics

Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Production of Antibiotics01:27

Production of Antibiotics

Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and <i>Pseudomonas aeruginosa</i>: Brief Summary.

Open forum infectious diseases·2025
Same author

Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and <i>Pseudomonas aeruginosa</i>.

Open forum infectious diseases·2025
Same author

Evaluation of Factors Predictive of Efficacy Among Patients With Complicated Urinary Tract Infection and/or Acute Pyelonephritis.

Open forum infectious diseases·2024
Same author

Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections.

Antimicrobial agents and chemotherapy·2024
Same author

Piperacillin/Tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations From the United States Committee on Antimicrobial Susceptibility Testing.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024
Same author

<i>In vivo</i> pharmacodynamic characterization of a next-generation polyene, SF001, in the invasive pulmonary aspergillosis mouse model.

Antimicrobial agents and chemotherapy·2024
Same journal

Generalizable AI predicts immunotherapy outcomes across cancers and treatments.

Nature medicine·2026
Same journal

Immune aging biomarkers for clinical trials.

Nature medicine·2026
Same journal

Lassa fever countermeasures gather pace.

Nature medicine·2026
Same journal

Why high scores do not mean application readiness for health AI.

Nature medicine·2026
Same journal

Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial.

Nature medicine·2026
Same journal

Biological aging might help to explain the rising risk of early-onset cancer.

Nature medicine·2026
See all related articles

Related Experiment Video

Updated: May 31, 2026

Antibiotic Dereplication Using the Antibiotic Resistance Platform
10:49

Antibiotic Dereplication Using the Antibiotic Resistance Platform

Published on: October 17, 2019

Antibiotic bill doesn't GAIN enough ground.

Paul G Ambrose1

  • 1Institute for Clinical Pharmacodynamics in Latham, New York, USA.

Nature Medicine
|July 9, 2011
PubMed
Summary
This summary is machine-generated.

New US legislation aims to combat antimicrobial resistance by incentivizing the antibiotic industry. However, it needs stronger protections against generic drug competition to effectively encourage investment and research.

More Related Videos

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

Related Experiment Videos

Last Updated: May 31, 2026

Antibiotic Dereplication Using the Antibiotic Resistance Platform
10:49

Antibiotic Dereplication Using the Antibiotic Resistance Platform

Published on: October 17, 2019

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

Area of Science:

  • Pharmaceutical Science
  • Infectious Disease Research
  • Health Policy

Background:

  • Antimicrobial drug resistance is a growing global health threat.
  • The antibiotic industry faces significant economic challenges, hindering new drug development.
  • Recent US legislation proposes incentives to stimulate antibiotic research and development.

Purpose of the Study:

  • To evaluate the potential effectiveness of proposed US legislation in addressing antimicrobial drug resistance.
  • To identify necessary improvements in the legislation to adequately incentivize the pharmaceutical industry.
  • To propose key policy changes for fostering antibiotic innovation.

Main Methods:

  • Analysis of proposed US legislative measures for antibiotic industry incentives.
  • Economic assessment of the impact of generic drug competition on antibiotic development.
  • Review of intellectual property, regulatory, and market access policies relevant to pharmaceuticals.

Main Results:

  • The current legislation may not sufficiently protect companies from generic drug competition.
  • Incentives proposed may not be adequate to overcome market barriers for new antibiotics.
  • Key areas for improvement include regulatory streamlining and market exclusivity.

Conclusions:

  • Proposed legislation requires significant revisions to effectively stimulate antibiotic research and development.
  • Enhanced protection from generic competition, simplified regulatory pathways, and market guarantees are crucial.
  • Addressing these policy gaps is essential to combat antimicrobial resistance through industry innovation.